[Skip to Navigation]
June 1983

The Effects of Calciferol and Its Metabolites on Patients With Chronic Renal Failure: II. Calcitriol, 1a-Hydroxyvitamin D3, and 24,25-Dihydroxyvitamin D3

Author Affiliations

From the Nephrology Section, Department of Medicine, University of Oklahoma Health Sciences Center, and the Veterans Administration Medical Center, Oklahoma City.

Arch Intern Med. 1983;143(6):1205-1211. doi:10.1001/archinte.1983.00350060129021

• The available data with regard to the use of calcitriol, 1α-hydroxyvitamin D3 (1α-OH D3), and 24,25-dihydroxyvitamin D3 (24,25-[OH]2D3) in the management of chronic renal insufficiency are reviewed. Patients with mild to moderate osteitis fibrosa experience substantial improvement with either calcitriol or 1α-OH D3 therapy. However, few patients experience a reversal to normal in histologic characteristics of bone. The conditions of patients with osteomalacia do not respond to either calcitriol or 1α-OH D3 therapy. The bone lesion appearing in these patients is most likely a toxic effect of aluminum. The prognosis is usually poor, but the conditions of some patients may respond to administration of 24,25-(OH)2D3 together with calcitriol. Preliminary data suggest that use of chelating agents may be beneficial. In this group of patients, 24,25-(OH)2D3 administration together with calcitriol may be beneficial.

(Arch Intern Med 1983;143:1205-1211)